TY  - JOUR
AU  - Fehrenbacher, Louis
AU  - von-Pawel, Joachim
AU  - Park, Keunchil
AU  - Rittmeyer, Achim
AU  - Gandara, David R
AU  - Ponce-Aix, Santiago
AU  - Han, Ji-Youn
AU  - Gadgeel, Shirish M
AU  - Hida, Toyoaki
AU  - Cortinovis, Diego L
AU  - Cobo, Manuel
AU  - Kowalski, Dariusz M
AU  - De-Marinis, Filippo
AU  - Gandhi, Mayank
AU  - Danner, Bradford
AU  - Matheny, Christina
AU  - Kowanetz, Marcin
AU  - He, Pei
AU  - Felizzi, Federico
AU  - Patel, Hina
AU  - Sandler, Alan
AU  - Ballinger, Marcus
AU  - Barlesi, Fabrice
PY  - 2018
DO  - 10.1016/j.jtho.2018.04.039
UR  - http://hdl.handle.net/10668/12488
T2  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
AB  - The efficacy and safety of atezolizumab versus the efficacy and safety of docetaxel as second- or third-line treatment in patients with advanced NSCLC in the primary (n = 850) and secondary (n = 1225) efficacy populations of the randomized phase III...
LA  - en
PB  - Elsevier
KW  - Atezolizumab
KW  - Cancer immunotherapy
KW  - Checkpoint inhibitor
KW  - Non–small cell lung cancer
KW  - PD-L1
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Agents
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Docetaxel
KW  - Female
KW  - Humans
KW  - Immunotherapy
KW  - Lung Neoplasms
KW  - Male
KW  - Survival Analysis
KW  - Treatment Outcome
TI  - Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.
TY  - research article
VL  - 13
ER  -